Form 4: Silence Therapeutics Director and 10% Owner Boosts Stake with Significant ADS Purchase
Insider Transaction Report
Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc, has acquired 39,305 American Depositary Shares, increasing his direct beneficial ownership.
Summary
- Richard Ian Griffiths, a Director and 10% owner of Silence Therapeutics plc (SLN), acquired 39,305 American Depositary Shares (ADSs) on June 12, 2025.
- Each ADS is immediately convertible into three ordinary shares, meaning this acquisition represents 117,915 ordinary shares.
- The acquisition price for the ADSs was $5.15 per share, resulting in a total transaction value of approximately $202,470.75.
- Following this transaction, Mr. Griffiths directly beneficially owns 11,361,380 ordinary shares of Silence Therapeutics plc.
- The transaction was made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan for the purchase of equity securities.
Sentiment
Score: 7
Explanation: The acquisition of shares by a director and 10% owner generally indicates confidence in the company's future, which is a positive signal for investors.
Positives
- A Director and 10% owner, Richard Ian Griffiths, increased his direct beneficial ownership in Silence Therapeutics plc by acquiring 39,305 American Depositary Shares (equivalent to 117,915 ordinary shares).
- Insider buying, especially by a significant shareholder and director, can signal strong confidence in the company's future prospects and valuation.
Future Outlook
The document, being a Form 4, reports a specific insider transaction and does not provide broader forward-looking statements or company guidance.
Industry Context
This Form 4 filing indicates an insider purchase within the biotechnology or pharmaceutical industry, where Silence Therapeutics operates. Such purchases are generally viewed as a positive signal of confidence in the company's future performance relative to its peers.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy Adherence | The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan designed to comply with insider trading regulations. | 06/12/2025 | Demonstrates adherence to regulatory best practices for insider trading, reducing potential for accusations of trading on material non-public information. |
Stakeholder Impact
- Shareholders: The insider purchase may be interpreted as a positive signal, potentially increasing investor confidence and demand for the company's stock.
Key Dates
| Date | Description |
|---|---|
| 06/12/2025 | Date of transaction for the acquisition of American Depositary Shares by Richard Ian Griffiths. |
| 06/13/2025 | Date the Form 4 was signed by Richard Ian Griffiths. |
Recommendation
holdKeywords
Silence Therapeutics, SLN, Form 4, Insider Trading, Beneficial Ownership, American Depositary Shares, ADS, Ordinary Shares, Director, 10% Owner, Richard Ian Griffiths, Stock Purchase, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.